Floatz logo

Rondecabtagene Autoleucel

Relapsed Non-Hodgkin Lymphoma

Lyell Immunopharma, Inc.Cell therapyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

410 Active assets in the Relapsed Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Rondecabtagene Autoleucel is also rated in:

relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
large B-cell lymphomaDormant
B
Indicative ·
59 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →